Fate Therapeutics announced promising preliminary clinical trial results for FT819, an investigational CAR T-cell therapy for people living with systemic lupus erythematosus (SLE) with lupus nephritis (LN), a serious complication of lupus that affects the kidneys.
This post was originally published on this site